Eyemaxx Real Estate AG
- WKN: A0V9L9
- ISIN: DE000A0V9L94
- Land: Deutschland
Nachricht vom 28.08.2019 | 11:39
Eyemaxx Real Estate AG : Approval of the securities prospectus for the 2019/2024 corporate bond
DGAP-News: Eyemaxx Real Estate AG / Key word(s): Issue of Debt/Miscellaneous
Eyemaxx: Approval of the securities prospectus for the 2019/2024 corporate bond
- Issuing volume of up to EUR 50 million, interest rate of 5.5 percent p.a.
- Public offering in Germany, Austria and Luxembourg from 5 to 19 September 2019
- Exchange period for the 2014/2020 bond from 30 August 2019 to 13 September 2019
- Funds to be used primarily for the refinancing of capital market liabilities falling due
Aschaffenburg, 28 August 2019 - Eyemaxx Real Estate AG (General Standard; ISIN: DE000A0V9L94; "Eyemaxx") has received today the approval of the securities prospectus for the issuing of a corporate bond with a volume of up to EUR 50 million, a five-year term and an interest rate of 5.5 percent p.a. from the Luxembourg Financial Supervisory Authority CSSF (Commission de Surveillance du Secteur Financier). The public offering in Germany, Austria and Luxembourg starts on 5 September 2019 and will probably end on 19 September 2019 (12:00 noon CEST). The period for the exchange of 2014/2020 notes (ISIN: DE000A12T374) into 2019/2024 notes (ISIN DE000A2YPEZ1) starts on 30 August 2019 and will end on 13 September 2019 (6pm CEST). The subscription is possible during the public offering through the subscription functionality of Deutsche Börse, the Xetra subscription tool "DirectPlace".
In addition to the public offering and the exchange offer, the notes are to be offered within the framework of a private placement to qualified investors as well as additional investors in accordance with the respectively applicable exemptions for private placements in Germany, Austria and Luxembourg as well as in certain additional states (with the exception of the USA, Canada, Australia and Japan). The private placement is carried out by Bankhaus Lampe KG as Sole Global Coordinator and Sole Bookrunner.
The 2019/2024 notes are to be included in the Quotation Board, a trading segment of the Open Market of the Frankfurt Stock Exchange. The listing is to commence on 24 September 2019.
Dr. Michael Müller, CEO of Eyemaxx: "We want to use the funds from the new bond primarily for the refinancing of capital market liabilities falling due, the financing of subordinate shareholder loans for a prompt implementation of our well-stocked project pipeline with a volume of around EUR 855 million, the start of our new real estate developments as well as the modernisation and acquisition of existing properties as a second pillar. We envisage both the modernisation of properties in our portfolio and the acquisition of new existing properties to further balance our business model. With the new bond we support our further corporate growth and have already now a very good basis with our many years of experience, the strong network and the focus on residential and commercial properties in Germany and Austria."
The 2019/2024 bond has a term from 24 September 2019 to 23 September 2024 included, with repayment of 100 percent of the nominal amount of EUR 1,000 per note on 24 September 2024. Interest is paid on an annual basis on 24 September and for the first time in 2020.
The 2019/2024 notes constitute direct, unconditional and unsubordinated liabilities (pari passu). Furthermore, a negative pledge and a limitation of the distribution of profits have been laid down: The equity determined on the basis of the IFRS consolidated financial statements may not fall below EUR 40.0 million and the equity ratio must amount to at least 25 percent. If these obligations are not met, the interest rate is increased on a non-recurring basis by 0.50 percent and applies until the defined levels of the equity and equity ratio have been reached again.
The offering is dependent on the approved securities prospectus. The latter is available on the website www.eyemaxx.com and can be obtained free of charge at the registered office of the company during regular business hours.
About Eyemaxx Real Estate AG
Eyemaxx' business activities take a dual-pronged approach. These include high-margin projects and also the continued expansion of its stocks of let commercial properties, which generate ongoing rental income and thus constant cash flows. In so doing, Eyemaxx uses the expertise offered by its experienced management team together with a strong team of real estate professionals, and also a well-established and broad network which opens up additional access to attractive properties and projects. As a result, the current project pipeline has been grown to total of around 855 million euros.
Shares of Eyemaxx Real Estate AG are listed in the General Standard of Frankfurt Stock Exchange and in the direct market plus on Vienna Stock Exchange. The company has also issued several bonds, which are also listed on the stock exchange.
You can find more information at www.eyemaxx.com
This communication is addressed exclusively to persons who are lawfully entitled to receive this information. Specifically, it is not addressed to U.S. citizens or persons resident in the United States of America (USA), Australia, Canada or Japan. This communication is not for distribution to, or publication in, the United States, and may not be distributed to, or brought into, or published in, any jurisdiction where such distribution or publication would be unlawful.
|Company:||Eyemaxx Real Estate AG|
|Phone:||+49 (0) 6021 386 69 17|
|Fax:||+49 (6021) 38 669 15|
|ISIN:||DE000A0V9L94, DE000A1TM2T3, DE000A12T374 , DE000A2AAKQ9 ,|
|WKN:||A0V9L9, A1TM2T, A12T37, A2AAKQ|
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange|
|EQS News ID:||864597|
|End of News||DGAP News Service|
Expedeon AG mit attraktiver Produktpipeline
Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.
Der AKTIONÄR News
15. Oktober 15:26 Amazon: „Das wird Bezos niemals zulassen“
15. Oktober 14:50 Brexit-Deal vor Abschluss? DAX schaltet in den Rallye-Modus
15. Oktober 14:10 Apple: Der nächste Mega-Kassenschlager?
15. Oktober 14:10 Update: Wirecard-Aktie kollabiert – jetzt verkaufen?
15. Oktober 13:50 Startschuss zur US-Berichtssaison – AKTIONÄR-Favorit überrascht mit ...
Original-Research: ITM Power Plc (von First Berlin Equity Research GmbH): Hinzufügen
15. Oktober 2019